Blue Trust Inc. Buys 1,310 Shares of Hologic, Inc. (NASDAQ:HOLX)

Blue Trust Inc. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 18.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,428 shares of the medical equipment provider’s stock after buying an additional 1,310 shares during the quarter. Blue Trust Inc.’s holdings in Hologic were worth $608,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter valued at approximately $25,000. General Partner Inc. bought a new stake in Hologic during the 4th quarter valued at $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new position in shares of Hologic during the 2nd quarter worth $37,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several recent research reports. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Up 1.1 %

Shares of Hologic stock opened at $72.17 on Friday. The firm’s 50 day simple moving average is $73.49 and its two-hundred day simple moving average is $78.11. The firm has a market capitalization of $16.29 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business posted $0.89 EPS. Analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.